University of Rochester Medical Center | Strategic Alliance Partners
One of the nation’s leading academic medical centers, the University of Rochester Medical Center forms the centerpiece of the University of Rochester’s health research, teaching and patient care missions. Over the last five years, URMC has garnered more than $1.3 billion in biomedical research, landing the University of Rochester School of Medicine and Dentistry in the top one-quarter of U.S. medical centers in federal research funding. As upstate New York’s premier health care delivery network, patients benefit from the Medical Center’s robust teaching and biomedical research programs. The University’s health care delivery network is anchored by Strong Memorial Hospital, an 886-bed, University-owned teaching hospital designated by the New York State Department of Health as a Level One Regional Trauma and Burn Center and home to Western New York’s only cardiac transplant program. With more than 26,000 part- and full-time employees, the Medical Center is the largest single component of the Rochester region’s leading employer.
Latest from University of Rochester Medical Center
Challenges and Opportunities in the Future of Health-System Pharmacy
January 31st 2023Moderator Curtis E. Haas, PharmD, FCCP; Deborah Simonson, PharmD; Andrew J. Donnelly, PharmD, MBA, FASHP; Noelle Chapman, PharmD, MBA, BCPS, FASHP; Todd Nesbit, PharmD, MBA, FASHP, discuss current challenges facing health-system pharmacies as well as potential solutions in areas such as staffing and financial stress.
Watch
Multiple Myeloma Therapy Often Causes Cardiovascular Complications
Many patients have baseline risk factors present at diagnosis because of older age and disease-related elements.
Read More
Preparing for the Waiting Period in the Pharmacy Following COVID-19 Vaccinations
December 23rd 2020Pharmacy Times® interviewed Michael Flannery, PharmD, the assistant director of pharmacy operations at the University of Rochester Medical Center, on the process for managing the waiting period in the pharmacy following COVID-19 immunizations.
Watch
340B: Emerging From the Shadows
May 1st 2018In this issue of Pharmacy Times® Health-System Edition, Grayson K. Peek, PharmD, and Halena Leah Marcelin, PharmD, offer a brief discussion of optimizing wholesale acquisition cost exposure for organizations participating in the federal 340B drug discount program when the group purchasing organization prohibition requirement applies.
Read More
An Introduction From New Editor-in-Chief Curtis E. Haas, PharmD, FCCP
March 15th 2018We face many challenges in this very dynamic practice environment, with the prospects of declining revenue, increasing costs, major changes in reimbursement models, and ever-increasing demands on departments of pharmacy to positively affect drug-related outcomes and quality of care.
Read More
